Recombinant Rat Palmitoyltransferase ZDHHC18 (Zdhhc18)

What is the primary function of ZDHHC18 in cellular biology?

ZDHHC18 functions as a palmitoyltransferase that catalyzes the addition of palmitate to specific protein substrates, notably HRAS. In physiological contexts, ZDHHC18 regulates protein localization and activity through this post-translational modification. Research has demonstrated that ZDHHC18 catalyzes HRAS palmitoylation, which is pivotal for its translocation to the plasma membrane and subsequent activation of downstream signaling cascades .

Additionally, ZDHHC18 plays a regulatory role in innate immunity through its interaction with cGAS (cyclic GMP-AMP synthase). The palmitoyltransferase activity of ZDHHC18 mediates cGAS palmitoylation, resulting in reduced binding affinity of cGAS to double-stranded DNA and subsequent attenuation of innate immune responses .

How is ZDHHC18 expression altered in pathological conditions?

ZDHHC18 expression is significantly elevated in pathological conditions associated with renal fibrosis. Studies using unilateral ureteral obstruction (UUO) and folic acid-induced (FA-induced) renal fibrosis mouse models have demonstrated marked upregulation of ZDHHC18. This elevated expression pattern has been corroborated in fibrotic kidney tissue samples from patients with chronic kidney disease (CKD) .

The increased expression of ZDHHC18 in fibrotic conditions appears to be functionally significant, as tubule-specific deletion of ZDHHC18 attenuates tubular epithelial cells' partial epithelial-mesenchymal transition (EMT) and reduces production of profibrotic cytokines, ultimately alleviating tubulointerstitial fibrosis. Conversely, ZDHHC18 overexpression exacerbates progressive renal fibrosis, highlighting its pathological role .

What experimental models are available for studying ZDHHC18 function?

Several experimental models have been established for investigating ZDHHC18 function:

When designing experiments, it's important to consider that ZDHHC18 functions may be compensated for by other ZDHHC family members (such as ZDHHC6 and ZDHHC9) in some contexts, as these enzymes can also catalyze similar palmitoylation reactions .

What are the molecular mechanisms underlying ZDHHC18-mediated regulation of renal fibrosis?

ZDHHC18 regulates renal fibrosis through a complex molecular pathway involving HRAS palmitoylation and subsequent signal transduction. The mechanistic pathway can be described as follows:

• ZDHHC18 catalyzes the palmitoylation of HRAS at cysteine residues 181 and 184

• This palmitoylation facilitates HRAS translocation to the plasma membrane

• Membrane-localized HRAS activates downstream MEK/ERK phosphorylation

• Activated MEK/ERK pathway promotes Ras-responsive element-binding protein 1 (RREB1)

• RREB1 enhances SMAD binding to the Snai1 and Has2 cis-regulatory regions

• This promotes transcription of EMT-related genes, driving fibrotic processes

Experimental evidence supports this mechanism, as mutation of the palmitoylation sites in HRAS (C181S and C184S) alleviates the partial EMT phenotype in proximal tubular epithelial cells (PTECs) . Furthermore, ZDHHC18 appears to serve as a critical link between TGF-β and RAS signaling pathways, as TGF-β1 promotes ZDHHC18 expression, creating a positive feedback loop that exacerbates fibrotic processes .

How does ZDHHC18 regulate innate immune responses through cGAS modification?

ZDHHC18 negatively regulates cGAS-mediated innate immunity through a palmitoylation-dependent mechanism. The detailed process involves:

• ZDHHC18 catalyzes the palmitoylation of cGAS

• This post-translational modification reduces cGAS binding affinity to double-stranded DNA

• Reduced DNA binding inhibits cGAS dimerization and activation

• Consequently, downstream signaling pathways including TBK1/IRF3 activation are suppressed

• This leads to decreased type I interferon production (specifically IFN-β)

This regulatory mechanism has been substantiated through multiple experimental approaches. ISD (interferon-stimulatory DNA) pull-down assays demonstrate that ZDHHC18 overexpression abrogates cGAS-DNA complex formation in a dose-dependent manner. Importantly, a catalytically inactive ZDHHC18 mutant (ZDHHC18(CS)) with a cysteine-to-serine substitution in the DHHC motif fails to inhibit cGAS-DNA interaction, confirming the dependence on enzymatic activity .

Functional assays using IFN-β luciferase reporter systems further validate this mechanism, showing that ZDHHC18 significantly reduces cGAS/STING-mediated IFN-β promoter activation in a dose-dependent manner, while the ZDHHC18(CS) mutant rescues this negative phenotype .

What computational methods are most effective for predicting ZDHHC18-substrate interactions?

Advanced computational approaches have been employed to analyze ZDHHC18 interactions with its substrates. The most effective methods include:

These computational approaches provide valuable insights into the structural basis of ZDHHC18-mediated palmitoylation. For example, PCA can identify correlated motions between specific residues, with positive Cij values indicating correlated motion and negative values representing inverse correlation .

When implementing these methods, researchers should consider that the accuracy of simulations depends heavily on parameter selection and simulation time. The binding free energy (ΔGbind) calculations are particularly useful for comparing the relative strength of different ZDHHC18-substrate interactions and can guide experimental validation strategies .

What are the optimal methodologies for generating and validating ZDHHC18 knockout models?

Generating reliable ZDHHC18 knockout models requires careful consideration of methodological approaches:

• CRISPR/Cas9-mediated genome editing:

  • Target selection: Exons 3-7 of ZDHHC18 have been successfully targeted

  • Delivery method: Co-injection of Cas9 and guide RNA (gRNA) into fertilized eggs

  • Validation: PCR analysis of genomic DNA and sequencing to confirm deletions

  • Breeding strategy: Heterozygous intercrossing to generate homozygous knockouts

• Considerations for phenotypic analysis:

  • Age standardization: 6-8 week old mice show consistent phenotypes

  • Sex differences: No significant differences in results between sexes have been reported

  • Controls: Littermate wild-type mice should be used as controls

  • Housing conditions: Specific pathogen-free animal facilities minimize confounding variables

• Cell-specific knockout approaches:

  • For renal studies, tubule-specific deletion of ZDHHC18 provides targeted insights

  • This approach allows discrimination between direct effects on tubular epithelial cells versus secondary effects on other cell types

  • Cell-specific knockouts help elucidate tissue-specific functions and avoid developmental compensation mechanisms

When validating knockout models, researchers should assess both genomic modifications and functional consequences through comprehensive analyses of palmitoylation activity, target protein localization, and downstream signaling pathway activation.

What techniques are most effective for measuring ZDHHC18-mediated protein palmitoylation?

Several complementary techniques can be employed to assess ZDHHC18-mediated protein palmitoylation:

For HRAS palmitoylation specifically, mutation of cysteine residues 181 and 184 to serine has proven effective in abrogating ZDHHC18-mediated palmitoylation, providing a valuable tool for functional validation studies .

How can researchers effectively investigate the cross-talk between ZDHHC18 and TGF-β signaling pathways?

The cross-talk between ZDHHC18 and TGF-β signaling represents a critical intersection in fibrotic processes. To investigate this relationship effectively:

• Sequential stimulation experiments:

  • Pre-treatment with TGF-β1 followed by assessment of ZDHHC18 expression

  • Evaluation of ZDHHC18-dependent changes in SMAD2/3 activation

  • Analysis of how TGF-β1-induced gene expression is modulated by ZDHHC18 knockout or overexpression

• Chromatin immunoprecipitation (ChIP) approaches:

  • ChIP-PCR can assess RREB1 binding to enhancer regions of Snai1 and Has2

  • Comparison between wild-type and ZDHHC18 knockout conditions reveals ZDHHC18-dependent effects

  • Sequential ChIP can determine co-occupancy of transcription factors at specific genomic regions

• Co-immunoprecipitation assays:

  • Evaluation of protein-protein interactions between SMAD2/3 and RREB1

  • Assessment of how these interactions are affected by ZDHHC18 status

  • Determination of the role of HRAS palmitoylation in mediating these interactions

Research has shown that ZDHHC18 knockout attenuates TGF-β1-induced expression of fibrotic genes, including Snai1 and Has2, demonstrating the functional significance of this cross-talk .

What are the potential therapeutic implications of targeting ZDHHC18 in kidney diseases?

ZDHHC18 represents a promising therapeutic target for kidney fibrosis based on several lines of evidence:

• ZDHHC18 expression is significantly upregulated in fibrotic kidneys from both mouse models and human CKD patients

• Tubule-specific deletion of ZDHHC18 attenuates renal fibrosis in experimental models

• ZDHHC18 functions at the intersection of TGF-β and RAS signaling pathways, both of which are implicated in fibrotic processes

• The enzymatic activity of ZDHHC18 provides a potentially druggable target

Future therapeutic strategies could include:

• Development of small molecule inhibitors specific to ZDHHC18 palmitoyltransferase activity

• RNA interference approaches to downregulate ZDHHC18 expression

• Gene therapy to deliver modified ZDHHC18 with altered substrate specificity

• Combination therapies targeting both ZDHHC18 and downstream effectors

How can multi-omics approaches advance our understanding of ZDHHC18 biology?

Integrative multi-omics approaches can provide comprehensive insights into ZDHHC18 biology:

Integration of these datasets can reveal how ZDHHC18-mediated palmitoylation influences multiple cellular processes simultaneously and identify potential compensatory mechanisms when ZDHHC18 function is compromised.